⏳ Fetching live dividend data...
Home › Calculator › ABBV Dividend Calculator 2026
AbbVie Inc. · NYSE
Price: $216.63 · Annual div: $6.74/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ABBV → $175.2K in 10 years · $1,417.54/month
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ABBV position with:
Real after-tax yield depends on where you live and how you hold ABBV.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 3.11% | 0.31% | $311 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.64% | -0.16% | $264 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.49% | -0.31% | $249 / yr |
| 🇬🇧 UK ISA | 0% | 3.11% | 0.31% | $311 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.84% | 0.04% | $284 / yr |
| 🇨🇦 TFSA | 0% | 3.11% | 0.31% | $311 / yr |
| 🇨🇦 CA Taxable | 25% | 2.33% | -0.47% | $233 / yr |
| 🇦🇺 Super (pension) | 15% | 2.64% | -0.16% | $264 / yr |
| 🇦🇺 AU Taxable | 30% | 2.18% | -0.62% | $218 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.29% | -0.51% | $229 / yr |
| 🇫🇷 FR Taxable | 30% | 2.18% | -0.62% | $218 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $6.74/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ABBV pays quarterly — 4 times per year. Next ex-div: TBD.
How ABBV compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ABBV sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ABBV dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“AbbVie DRIP calculator with payout ratio analysis. The high payout ratio concerned me, but the free cash flow score section gave me reassurance. This is the depth I was looking for.”
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →